Trials Annotator

Trial NCT00090779

Org. Study IDs: ACTG A5217
Secondary IDs: 1U01AI068636 ACTG A5217 AIEDRP AIN503

Last trial update was posted on 2018-10-11

MeSH Interventions

Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Lopinavir Ritonavir Tenofovir

MeSH Conditions

HIV Infections

Other Conditions

Stopping Reasons

The DSMB concluded that the findings regarding the primary analysis would persist and that no additional study goals would be achieved by continuing the study.

Limitations And Caveats

N/A

Result Publications

Messer K, Vaida F, Hogan C. Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217. Contemp Clin Trials. 2006 Dec;27(6):506-17. doi: 10.1016/j.cct.2006.07.003. Epub 2006 Jul 25. [PMID: 16962381] [DOI: 10.1016/j.cct.2006.07.003]
Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S; A5217 Study Team. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012 Jan 1;205(1):87-96. doi: 10.1093/infdis/jir699. Epub 2011 Dec 15. [PMID: 22180621] [DOI: 10.1093/infdis/jir699]

Annotations

Category Annotations

No annotators decided on categories yet

Intervention Annotations

#	Outdated	Intervention				Condition
#	Outdated	Name		Route	DrugBank ID	Condition